EA201691343A1 - Гетероарилзамещенные никотинамидные соединения - Google Patents

Гетероарилзамещенные никотинамидные соединения

Info

Publication number
EA201691343A1
EA201691343A1 EA201691343A EA201691343A EA201691343A1 EA 201691343 A1 EA201691343 A1 EA 201691343A1 EA 201691343 A EA201691343 A EA 201691343A EA 201691343 A EA201691343 A EA 201691343A EA 201691343 A1 EA201691343 A1 EA 201691343A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
pyridinyl
pyrrolo
heteroaryl substituted
nicotinamide compounds
Prior art date
Application number
EA201691343A
Other languages
English (en)
Inventor
Джозеф Б. Сантелла
Сриканта Ратна Кумар
Джон В. Дунсиа
Дэниэл С. Гарднер
Венкатрам Редди Пайди
Сатиш Кесаван Наир
Джон Хайнс
Хун Ву
Натесан Муругесан
Кандхасами Саркуна М
Пираманайгам Аруначалам
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52355270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691343(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201691343A1 publication Critical patent/EA201691343A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описаны соединения формулы (I)или их соли, где НЕТ представляет собой гетероарил, выбранный из пиразолила, индолила, пирроло[2,3-b]пиридинила, пирроло[2,3-d]пиримидинила, пиразоло[3,4-b]пиридинила, пиразоло[3,4-d]пиримидинила, 2,3-дигидро-1H-пирроло[2,3-b]пиридинила, имидазо[4,5-b]пиридинила и пуринила, где указанный гетероарил замещен Rи R; и Rи Rопределены в настоящем документе. Также описаны способы применения таких соединений в качестве модуляторов IRAK4 и фармацевтические композиции, содержащие такие соединения. Указанные соединения используются для лечения, профилактики или сдерживания развития воспалительных и аутоиммунных заболеваний.
EA201691343A 2014-01-03 2015-01-02 Гетероарилзамещенные никотинамидные соединения EA201691343A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Publications (1)

Publication Number Publication Date
EA201691343A1 true EA201691343A1 (ru) 2016-11-30

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691343A EA201691343A1 (ru) 2014-01-03 2015-01-02 Гетероарилзамещенные никотинамидные соединения

Country Status (21)

Country Link
US (1) US9169252B2 (ru)
EP (1) EP3089973B1 (ru)
JP (1) JP6475252B2 (ru)
KR (1) KR20160101191A (ru)
CN (1) CN106061967B (ru)
AR (1) AR098991A1 (ru)
AU (1) AU2015204045A1 (ru)
CA (1) CA2935329A1 (ru)
CL (1) CL2016001706A1 (ru)
EA (1) EA201691343A1 (ru)
ES (1) ES2804707T3 (ru)
IL (1) IL246474A0 (ru)
MA (1) MA39162A1 (ru)
MX (1) MX2016008723A (ru)
PE (1) PE20161292A1 (ru)
PH (1) PH12016501164A1 (ru)
SG (1) SG11201605340QA (ru)
TN (1) TN2016000271A1 (ru)
TW (1) TW201609693A (ru)
UY (1) UY35935A (ru)
WO (1) WO2015103453A1 (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014074675A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2935392C (en) * 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
WO2016210034A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) * 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JOP20180011A1 (ar) * 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
KR20200036913A (ko) * 2017-08-04 2020-04-07 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
AU2019220632B2 (en) 2018-02-14 2024-02-22 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2023008973A1 (ko) * 2021-07-29 2023-02-02 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
EP4367118A1 (en) 2021-08-18 2024-05-15 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
DE60232510D1 (de) 2001-06-15 2009-07-16 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
WO2004002964A1 (ja) 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. ジアミノピリミジンカルボキサミド誘導体
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2164841A1 (en) 2007-06-08 2010-03-24 Bayer CropScience SA Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
CA2745004C (en) * 2008-11-28 2014-07-15 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
WO2010144647A1 (en) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
JP5770198B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ.ベー. オピオイド受容体調節因子としてのフェノキシ置換ピリミジン
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 작동약
MX2013012588A (es) 2011-04-29 2014-05-20 Icahn School Med Mount Sinai Inhibidores de cinasa.
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
EP2802579B1 (en) * 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104159896B (zh) * 2012-01-13 2017-05-24 百时美施贵宝公司 用作激酶抑制剂的杂环取代的吡啶基化合物
MX2015005272A (es) 2012-11-08 2015-07-14 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa).
US9546153B2 (en) * 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014074675A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators

Also Published As

Publication number Publication date
MA39162A1 (fr) 2017-12-29
TW201609693A (zh) 2016-03-16
UY35935A (es) 2015-06-30
AU2015204045A1 (en) 2016-08-18
SG11201605340QA (en) 2016-07-28
EP3089973A1 (en) 2016-11-09
US20150191464A1 (en) 2015-07-09
CN106061967B (zh) 2019-04-19
AR098991A1 (es) 2016-06-22
JP2017501202A (ja) 2017-01-12
PH12016501164A1 (en) 2016-08-15
ES2804707T3 (es) 2021-02-09
KR20160101191A (ko) 2016-08-24
US9169252B2 (en) 2015-10-27
CN106061967A (zh) 2016-10-26
CA2935329A1 (en) 2015-07-09
PE20161292A1 (es) 2016-11-23
TN2016000271A1 (en) 2017-10-06
EP3089973B1 (en) 2020-04-29
WO2015103453A1 (en) 2015-07-09
MX2016008723A (es) 2016-09-07
JP6475252B2 (ja) 2019-02-27
IL246474A0 (en) 2016-08-31
CL2016001706A1 (es) 2017-02-10

Similar Documents

Publication Publication Date Title
EA201691343A1 (ru) Гетероарилзамещенные никотинамидные соединения
MX2021011438A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.
SI3555097T1 (sl) Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz
MX2018015422A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridini lo.
EA201990657A1 (ru) Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MX352831B (es) Cristales de sal.
DK3489238T3 (da) Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser
MA50375A (fr) Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
EA201791369A1 (ru) Твердые формы конденсированных гетероароматических пирролидинонов
WO2014172513A3 (en) 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors
EA201891897A1 (ru) 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
EA201300997A1 (ru) ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
JP2016517877A5 (ru)
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
MA47070A (fr) Pyrazolo[3,4-b]pyridines et imidazo[1,5-b]pyridazines utilisés en tant qu'inhibiteurs de pde1
AR114923A1 (es) Compuestos de heteroaril heterociclilo para el tratamiento de enfermedad autoinmunitaria
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak